CORRECTED-Aurora Spine Q4 revenue rises 6.8%

Overview

• Spinal implant maker's Q4 revenue rose 6.8% yr/yr

• Q4 EBITDAC improved to $301,112 from a loss in prior year period

• Revenue growth driven by higher Zip implant, SI fusion device sales and new biologics launch

Outlook

• Company expects sales of DEXA product line to build throughout 2026

Result Drivers

• PRODUCT MIX - Higher gross margin attributed to increased sales of higher-margin implants, lower distributor commissions, and reduced royalty expenses

• ZIP AND SI FUSION SALES - Revenue growth driven by increased sales in Zip implants and SI fusion devices, as well as the release of the facet fusion device

• BIOLOGICS LAUNCH - Launch of Aurora Biologics contributed to a $0.2 mln increase in biologic sales for 2025, with most growth in the second half

Company press release: ID:nGNX99X42X

Key Details

Analyst Coverage

• The stock recently traded at 2 times the next 12-month earnings vs. a P/E of 2 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.